Our "What Are Your Top 20 Drugs?" survey launched for second and fourth-year Georgetown medical students earlier this month. We look forward to seeing if drug choices differ by level of training, and analyzing the results alongside the original survey.
On April 6th, Dr. Fugh-Berman was quoted in Paul Thacker's Slate article "How to Handle FDA Rejection" about the misperception that the FDA has not approved Flibanserin (a "female Viagra" drug) due to sexism.
On April 11th, Dr. Fugh-Berman was quoted in The Boston Herald stating that the campaign to retract a recent JAMA study linking testosterone drugs to heart attacks, stroke and death "smells like industry influence."
On April 16th, Dr. Fugh-Berman was quoted in this NPR story on a recent study showing that when dermatologists give patients free samples, they end up prescribing medication more than twice as expensive as prescriptions in sample-free offices. "When a doctor gives a sample to a patient, it's a very strong endorsement of a drug," Dr. Fugh-Berman said, and it would look "inconsistent" if they later prescribed a different generic drug.
PharmedOut recruited physicians and researchers to sign one of several letters to FDA Commissioner Margaret Hamburg, asking the FDA not to approve Roche's Cobas HPV test as an alternative to a Pap smear for cervical cancer screening. The FDA approved the test, and the letters were mentioned in the coverage by the New York Times and AP.
PharmedOut's Resource of the Month: A full list of PharmedOut's media mentions over the years can be foundon our website.
April's PharmedOut Fodder: Transparency
The topic of transparency came up in two major stories this month: For the first time, CMS released a searchable database on what procedures were covered by Medicare during the 2011 fiscal year, for which physicians, and how much they cost. Among the findings was that two percent of physicians accounted for a quarter of all Medicare payments, and one-quarter of physicians accounted for three-quarters of all payments.
In addition, JAMA published a research paper on how many leaders of academic medical centers also serve on boards of pharmaceutical companies. The answer is that "nearly 40 percent of drug makers worldwide — and nearly every U.S. pharmaceutical manufacturer — had at least one board member who simultaneously served in a leadership position at such centers in 2012." Given that many of these centers have conflict-of-interest policies that prohibit faculty members from accepting drug company gifts, how can they "allow their leaders to serve on the boards of firms that pay them on average over $300,000 per year?", asks The Atlantic.
These news items spawned a large amount of analyses and discussion about conflicts of interest and transparency in healthcare. Proponents say the public needs and deserves to know this information. Especially in the case of Medicare data, clarity on costs may help reduce waste and salvage the program for the future. Opponents — such as some of the called-out physicians— say the payment data lacks necessary context, making it misleading to patients and others.
Combined with the Physician Payments Sunshine Act reports, which were due to HHS this past March 31 and will be made available this fall, perhaps we'll see a rising interest in bringing transparency to the healthcare system. Currently, the vast majority of healthcare consumers do not know the costs of what they are paying for, which some believe is a problem.
While these stories both centered on transparency, one represents a demand for previously confidential data, and the other represents the initiative to amalgamate publicly available information. PharmedOut emphasizes both strategies in tackling issues related to transparency.
*** News Round-Up (for more, please follow @pharmed_out on Twitter!)
The National Center for Health Research (previously the National Research Center for Women & Families) will hold their annual Foremothers Award Luncheon in D.C. on May 9th, and are offering a discount for those who mention PharmedOut. This year's event will honor "Health Policy Heroes" Charles Ornstein and Tracy Weber of ProPublica, who have covered many stories related to the Medicare data release, Sunshine Act, and much more. Details and registration instructions are here.
Please join Dr. Carl Elliott's call-in campaign for an investigation into the death of Dan Markingson, who committed suicide while participating in a psychiatric study at the University of Minnesota.
"What Evidence is Essential for New Medical Products? Implications for Patients and Health Policy", an event highlighting the public health implications of medical product regulation criteria, will take place June 13th at the American Association for the Advancement of Science. Register for free here.